You hit your first meaningful revenue milestone. Maybe it’s $5M ARR, maybe it’s a handful of health system contracts, maybe it’s a cleared device with a few dozen happy surgeons. The momentum feels real. The board is encouraged. You’re hiring.
Then something shifts. The pipeline slows. Deals take longer to close. The champion inside the hospital loves you, but nothing moves. You’re not losing, exactly. You’re just stuck.
This pattern is so common in medtech that it has an unofficial name among investors and operators who’ve seen it enough times: the traction trap. You earned early wins through sheer force of will, founder relationships, and a product that solved a real problem for a specific set of believers. But the same circumstances that created early success often hide the structural gaps that prevent scale.
This is a medtech commercial strategy problem, and it’s one of the most predictable inflection points in scaling a medical device company. Here’s what’s actually happening.
Why Early Medtech Sales Don’t Translate to a Scalable Go-To-Market Strategy
The first ten customers in medtech are almost always founder-led. The CEO knows the clinical problem intimately, can speak the language of the physician, and brings a level of passion and credibility that no sales rep can replicate. Those early deals close because of trust in a person, not confidence in a commercial system.
The problem is that founders often look at those first ten wins and assume the model works. It doesn’t, not at scale. What worked was them. And you cannot clone yourself.
What most medtech CEOs discover too late is that they never actually built a repeatable medtech go-to-market strategy. They built a series of one-off transactions dressed up as a pipeline. The messaging that worked in a 1:1 founder conversation doesn’t translate to a sales deck. The clinical evidence that convinced an early adopter isn’t formatted in a way that satisfies a value analysis committee. The ROI that was obvious to a forward-thinking department head is invisible to a hospital CFO.
Scalable growth in medtech requires codifying what worked in those early deals and engineering it into a system. That means defined ICP criteria, a clinical value narrative that holds up without you in the room, and a medtech sales process designed around how hospitals actually buy, which is nothing like how most software companies sell.
Hospital Adoption in Medtech Is a Multi-Stakeholder Problem, and Most Companies Only Solve One Layer
Here is something that trips up even experienced medtech leaders: clinical enthusiasm does not equal institutional adoption. A surgeon or clinical champion who loves your product is a necessary condition. It is not a sufficient one.
Hospital adoption for medical devices, especially for anything with a meaningful budget or procedural implication, runs through layers that most early-stage companies have never systematically mapped. The physician champion, the department head, supply chain, the value analysis committee, finance, sometimes IT, sometimes legal. Each stakeholder has a different definition of value, a different risk tolerance, and a different set of objections.
Companies that stall after early traction are almost always selling to one layer. The surgeon is sold. But nobody ever addressed supply chain’s concern about vendor consolidation, or finance’s question about reimbursement risk, or the value analysis committee’s request for comparative cost data.
This is not a sales problem. It’s a medtech market access strategy problem. And it doesn’t get solved by hiring more reps. It gets solved by building the right content, evidence, and tools for each decision-maker in the chain, and training your commercial team to navigate the full ecosystem.
How Reimbursement Strategy Quietly Becomes a Medtech Growth Barrier
One of the most common and most dangerous assumptions in medtech is that reimbursement is “figured out” because there’s an existing CPT code or a coverage policy that technically applies. That’s not the same thing as a clear, predictable reimbursement pathway for your customer.
Physicians and hospital administrators are not going to take on reimbursement risk on your behalf. If there is ambiguity about coverage, prior authorization requirements, or expected payment rates, that ambiguity translates directly into sales friction. In many cases, the deal doesn’t die in a conversation. It just never comes back up.
Medtech reimbursement strategy has to be a commercial priority, not a back-office function. That means proactively understanding the payer landscape, building reimbursement support tools for your customers, and in some cases making strategic decisions about which geographies or care settings to prioritize based on coverage clarity. CEOs who treat reimbursement as a solved problem because they have a code often find out otherwise when they try to understand why their pipeline conversion rate is stuck at 20%.
Clinical Evidence Gaps and Their Impact on Medical Device Commercialization at Scale
You got cleared. Maybe you even have a handful of published studies or solid registry data. That felt like enough to get to market, and it probably was. But the evidence requirements that got you your first twenty accounts are not the same as what you’ll need at 200, or at a major IDN negotiation.
Health systems increasingly want health economic data, real-world evidence, and outcomes data in formats that align with their own quality metrics and cost benchmarks. The academic publication that your clinical advisor is proud of may not answer the specific question a hospital administrator is asking.
This creates a compounding medical device commercialization challenge because clinical evidence takes time to generate. Companies that don’t start planning their next evidence layer while still celebrating early commercial wins often find themselves in a situation where their commercial ambitions outpace their clinical credibility. They’re asking larger, more sophisticated customers to take a leap of faith that those customers won’t take.
The good news is that real-world evidence generation can often be designed into your commercial program rather than treated as a separate clinical affairs project. But it requires intention and early investment.
Why Medtech Marketing Strategy Often Gets Confused With Activity
Most medtech companies between $2M and $20M in revenue have a marketing function that is primarily producing content and attending conferences. That’s not the same as medtech marketing strategy that drives commercial outcomes.
Marketing that actually supports medtech revenue growth requires a clear point of view on the clinical and economic problem, content and education tools mapped to each stage of the buyer journey, account-based strategies for priority health systems, and physician education programs that create informed champions rather than just awareness.
A lot of early-stage medtech marketing is aimed at generating visibility without a clear theory of how that visibility converts to pipeline. The trade show booth, the journal ad, the KOL dinner — these things can be valuable, but only when they’re part of a connected commercial strategy. When they’re not, they’re expensive noise.
As a CEO, if you can’t articulate the specific role each marketing activity plays in advancing a deal or building account momentum, that activity probably needs to be redesigned or cut.
Building the Right Commercial Team Structure to Support Medtech Growth Strategy
Early commercial hires in medtech are often generalists who thrive in ambiguity. They’re scrappy, relationship-driven, and willing to do whatever it takes. That profile is exactly right for the zero-to-one phase.
But medtech growth strategy at scale requires different skills. It requires people who can build and follow repeatable processes, who can work effectively in a complex multi-stakeholder sales environment, who can articulate clinical and economic value in formal settings. The rep who closes deals on personality alone often struggles when the sale gets complicated.
This doesn’t mean those early people have to go. But it does mean that CEOs have to be honest about whether their team structure and the capabilities within it are designed for where they’re trying to go, not where they’ve been.
What to Do About a Medtech Revenue Growth Stall
Growth stalls in medtech are rarely about the product. If you have real clinical evidence and a product that delivers meaningful outcomes, you have the foundation. The stall is almost always about the commercial and market access architecture around the product.
The diagnostic question worth asking: are you growing because you’ve built a system, or because you have strong people working very hard? Both can produce similar results at small scale. Only one of them compounds.
The companies that break through the traction plateau are the ones that get honest about that question early enough to do something about it. They invest in commercial infrastructure before they need it, not after the board starts asking hard questions. They treat market access, clinical evidence, and hospital adoption as strategic priorities, not support functions. And they build marketing that is actually connected to how their customers make decisions.
That’s the work. It’s harder than building the product in most cases, and in medtech, it’s just as important.
Frequently Asked Questions
Why do medical device companies stall after early sales?
Most medical device companies stall not because the product stops working, but because the early commercial model doesn’t scale. Early deals are typically founder-led and relationship-driven. When companies try to grow beyond that initial base, they discover they never built a repeatable sales process, a multi-stakeholder hospital adoption strategy, or a market access infrastructure. The product is sound. The commercial architecture around it isn’t.
How do you scale a medtech company past early traction?
Scaling past early traction in medtech requires codifying what made early deals work, building a commercial system that operates without the founder, addressing all stakeholder layers in the hospital buying process, and ensuring reimbursement pathways are clear and well-supported for customers. Marketing and clinical evidence strategy need to evolve alongside the commercial ambition.
What is the biggest challenge in medical device commercialization?
Hospital adoption is consistently the biggest challenge. It’s not a single decision made by a single buyer. A medical device purchase moves through physicians, department heads, value analysis committees, supply chain, and finance. Most early-stage companies only effectively address one or two of those layers, which creates deals that stall or never close despite strong clinical interest.
How do hospitals make purchasing decisions for medical devices?
Hospital purchasing decisions for medical devices typically involve a formal evaluation process that includes clinical champions, department heads, the value analysis committee (VAC), supply chain, and finance. The VAC in particular evaluates clinical evidence, cost data, reimbursement viability, and outcomes data. Vendors who can speak to all of those dimensions with relevant materials are significantly more likely to close and move through adoption efficiently.
Why is reimbursement a barrier to medtech growth?
Reimbursement becomes a growth barrier when companies assume that having a billing code equals a clear pathway for customers. In reality, ambiguity around payer coverage, prior authorization, and payment rates creates risk that hospitals and physicians are unwilling to absorb. Without proactive reimbursement support tools and a defined payer strategy, that risk shows up as stalled deals and slow pipeline conversion.
What does a fractional Chief-Marketing Officer (CMO) do for a medtech company?
A fractional CMO for a medtech company provides senior marketing and commercial strategy leadership without the cost of a full-time executive. This typically includes building the go-to-market strategy, developing clinical and economic value messaging, creating market access and hospital adoption frameworks, overseeing marketing programs, and aligning the commercial team around a repeatable growth model. It’s particularly valuable for companies between $3M and $30M in revenue that need strategic leadership but aren’t ready for a full-time hire.
How do you build a repeatable sales process in medtech?
A repeatable medtech sales process starts with a clearly defined ideal customer profile, a clinical value narrative that works without the founder in the room, stage-by-stage guidance for navigating the hospital buying process, and tools tailored to each stakeholder group. It also requires a feedback loop between what’s working in the field and how the process is being refined over time.
Want to talk through where the gaps are in your commercial model? I work with high-growth medtech companies as a fractional CMO, helping leadership teams build the marketing and market access infrastructure to scale past early traction.
